Research and Markets: Research and Development on Crohn's Disease & Ulcerative Colitis

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=461212) has announced the addition of “Therapeutic Clinical Intelligence-Inflammatory Bowel Disease” to their offering.

This report is a competitive intelligence on the clinical trials of products on the market and in the development for Crohn's Disease & Ulcerative Colitis.

Crohn’s Disease Market

In 2007, Remicade (infliximab/Anti-TNF-?), the current market leader in the treatment of moderate-to-severe Crohn’s Disease (CD), is expected to experience fierce challenges for patient share from 2-3 new Anti-TNF class competitors; Humira, Tysabri, Cimzia. Humira (adalimumab) was approved in January 2007 for CD and will compete with Remicade based upon relative efficacy & convenience (Pen Injector); while despite the fact that Tysabri’s (natalizumab/VLA-4) safety will dampen initial uptake, the product’s novel mechanism and efficacy could enable it to capture share within the more severe patient segment. Cimzia’s (certolizumab pegol) 2007 planned launch may be postponed due to FDA regulatory delays, forcing UCB Pharma to conduct an additional study-and making a 2008 launch much more plausible.

Ulcerative Colitis Market

Similarly, the competitive landscape for Ulcerative Colitis (UC) treatments has the potential to shift over the next 2-4 years as more products are undergoing late-phase clinical trials in an attempt to maximize exposure in the IBD therapeutic area and garner share from UC market-leader Remicade. In particular, competitive threats to Remicade may come from programs including; Humira & Orencia recently initiated large phase III studies in moderate-to-severe UC, Tysabri is expected to commence trials in UC in 2007, and novel pipeline programs such as Nuvion (visilizumab) continue to progress.

Scope of Report

The scope of this report will concentrate on the Research & Development (R&D) competitive landscape for moderate-to-severe CD & UC therapeutics. The focus of the intelligence is on the clinical elements of competitive products from a clinical perspective; which provides insight into the strategic opportunities and challenges facing drug developers and marketers. Specifically, the focus of our analysis is on the clinical trial protocol designs and data results for 15 compounds in phase II or beyond that have the potential to alter the market dynamics in IBD over the next 5-7 years.

Contents:

- Executive Summary

- The Market Leader-Remicade

- Current & Future Competitors in IBD

- Products to Watch

- On the Radar-Future Development Plan Uncertain

- Appendix

- Figures and Tables Included

For more information visit: http://www.researchandmarkets.com/reportinfo.asp?report_id=461212.